Women who test positive for an inherited pathogenic/likely pathogenic gene variant in BRCA1, BRCA2, PALB2, CHEK2 and ATM are at an increased risk of developing certain types of cancer—specifically breast (all) and epithelial ovarian cancer (only BRCA1, BRCA2, PALB2). Women receive broad cancer risk figures that are not personalised (e.g., 44–63% lifetime risk of breast cancer for those with PALB2). Broad, non-personalised risk estimates may be problematic for women when they are considering how to manage their risk. Multifactorial-risk-prediction tools have the potential to deliver personalised risk estimates. These may be useful in the patient’s decision-making process and impact uptake of risk-management options. This randomised control trial (registration number to follow), based in genetic centres in the UK and US, will randomise participants on a 1:1 basis to either receive conventional cancer risk estimates, as per routine clinical practice, or to receive a personalised risk estimate. This personalised risk estimate will be calculated using the CanRisk risk prediction tool, which combines the patient’s genetic result, family history and polygenic risk score (PRS), along with hormonal and lifestyle factors. Women’s decision-making around risk management will be monitored using questionnaires, completed at baseline (pre-appointment) and follow-up (one, three and twelve months after receiving their risk assessment). The primary outcome for this study is the type and timing of risk management options (surveillance, chemoprevention, surgery) taken up over the course of the study (i.e., 12 months). The type of risk-management options planned to be taken up in the future (i.e., beyond the end of the study) and the potential impact of personalised risk estimates on women’s psychosocial health will be collected as secondary-outcome measures. This study will also assess the acceptability, feasibility and cost-effectiveness of using personalised risk estimates in clinical care.
25 September 2024 in Journal of Community Genetics
Background: Multifactorial cancer risk prediction tools, such as CanRisk, are increasingly being incorporated into routine healthcare. Understanding risk information and communicating risk is challenging and healthcare professionals rely substantially on the outputs of risk prediction tools to communicate results. This work aimed to produce a new CanRisk report so users can directly access key information and communicate risk estimates effectively. Methods: Over a 13-month period, we led an 8-step co-design process with patients, the public, and healthcare professionals. Steps comprised 1) think aloud testing of the original CanRisk report; 2) structured feedback on the original report; 3) literature review; 4) development of a new report prototype; 5) first round of structured feedback; 6) updating the new report prototype; 7) second round of structured feedback; and 8) finalising and publishing the new CanRisk report. Results: We received 56 sets of feedback from 34 stakeholders. Overall, the original CanRisk report was not suitable for patients and the public. Building on the feedback, the new report has an overview of the information presented: section one summarises key information for individuals; sections two and three present information for healthcare professionals in different settings. New features also include explanatory text, definitions, graphs, keys and tables to support the interpretation of the information. Discussion: This co-design experience shows the value of collaboration for the successful communication of complex health information. As a result, the new CanRisk report has the potential to better support shared decision-making processes about cancer risk management across clinical settings.
Breast cancer risk prediction tools are increasingly used in clinical practice to guide early detection, prevention, and shared decision-making. Unlike population-level screening, personalised risk estimates incorporate individual factors (family history, genetics, lifestyle, breast density), providing tailored assessments. These tools show promise for improving patient engagement and targeted prevention, but require effective implementation to ensure they enhance rather than complicate care. This review explores healthcare professionals’ experiences with providing personalised breast cancer risk estimates and women’s experiences of receiving them in clinical settings. Four online databases were searched for qualitative studies on the use of personalised risk estimates in clinical practice. Data were analysed using inductive thematic analysis. Seven papers were included; the majority based in the UK screening setting. Most used interview and focus-groups, with thematic analysis. Both healthcare professionals and women expressed high acceptance of personalised risk estimates. Women found the information empowering and useful for future health planning. Effective communication and prompt follow-up from healthcare professionals were crucial for positive experiences. Professionals highlighted challenges in implementation, including the need for additional healthcare professionals, safe care pathways, and technology. The studies focused on stratified breast screening, raising questions about offering less frequent screening to lower-risk women. This approach must be supported by strong evidence, and women should retain choice in screening intervals. Personalised risk estimates are favourably viewed in clinical practice, but studies mainly examined research settings. Further research is needed to understand real-world implementation, identify barriers, and optimise use across diverse clinical environments.
The CanRisk tool allows healthcare professionals to calculate validated multifactorial estimates of breast, ovarian, and prostate cancer risk. To support patient involvement in risk assessment, we co-designed a public-facing tool, MyCanRisk, which allows patients to collect and share risk information in advance of a clinical appointment, without generating risk estimates. This study describes the user-centred development of MyCanRisk and its initial evaluation. Development involved co-design workshops with patients, public contributors, healthcare professionals, and researchers, followed by iterative accessibility and usability testing against WCAG 2.2. Evaluation used a multi-methods design: 51 women with a family history of breast cancer completed MyCanRisk and, approximately two weeks later, a structured clinical-style interview. Agreement in risk categorisation was assessed using Cohen’s kappa. Semi-structured interviews with a purposive subsample (n=15) explored user experiences. MyCanRisk was perceived as accessible and easy to use. Agreement between MyCanRisk and structured interviews for risk categorisation was substantial (κ = 0.81, 95% CI 0.65–0.97). Discrepancies mainly reflected difficulties recalling detailed family history, such as ages at diagnosis and dates of birth/death. Participants valued the stepwise flow and asynchronous completion but reported challenges when their knowledge was incomplete. Suggested improvements included options to record approximate or unknown data and greater flexibility to update submissions. MyCanRisk has the potential to reduce data collection burden during clinical encounters, support patient preparation for risk assessment, and streamline cancer risk assessment pathways. With further refinement and testing in more diverse populations, it may facilitate earlier identification of individuals at increased cancer risk.